Abstract
The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1165-1174 |
| Number of pages | 10 |
| Journal | Expert Opinion on Biological Therapy |
| Volume | 5 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2005 |
Fingerprint
Keywords
- Cetuximab
- EGFR antibodies
- EGFR inhibitors
- EGFR tyrosine kinase inhibitors
- Erlotinib
- Gefitinib
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
- Clinical Biochemistry
Cite this
Epidermal growth factor inhibition in solid tumours. / Ganti, Apar Kishor P; Potti, Anil.
In: Expert Opinion on Biological Therapy, Vol. 5, No. 9, 01.09.2005, p. 1165-1174.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Epidermal growth factor inhibition in solid tumours
AU - Ganti, Apar Kishor P
AU - Potti, Anil
PY - 2005/9/1
Y1 - 2005/9/1
N2 - The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned.
AB - The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned.
KW - Cetuximab
KW - EGFR antibodies
KW - EGFR inhibitors
KW - EGFR tyrosine kinase inhibitors
KW - Erlotinib
KW - Gefitinib
UR - http://www.scopus.com/inward/record.url?scp=24144461280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24144461280&partnerID=8YFLogxK
U2 - 10.1517/14712598.5.9.1165
DO - 10.1517/14712598.5.9.1165
M3 - Review article
C2 - 16120047
AN - SCOPUS:24144461280
VL - 5
SP - 1165
EP - 1174
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 9
ER -